Orexo Interim Report Q3 2017
Financial overview Q3 2017 · Total net revenues SEK 166.2 million (181.9) · Zubsolv® US net revenue SEK 121.1 million (142.4) · EBIT SEK 40.9 million (43.0) · EBITDA SEK 46.1 million (50.9) · Earnings per share, before and after dilution, SEK 0.82/0.81 (1.04/1.04) · Cash flow from operating activities SEK 92.3 million (31.1) · Cash and cash equivalents SEK 370.7 million (276.9) · Guidance of full year 2017 positive EBITDA is confirmed Financial overview YTD 2017 · Total net revenues SEK 452.6 million (521.2) · Zubsolv US net revenue SEK 359.3 million (